Patents by Inventor David Beer
David Beer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200316901Abstract: A multi-layered infrared reflective material having a layer of an infrared reflective material, and a layer of an infrared transmissive, anti-reflective material, applied directly or indirectly to the infrared reflective material layer, the infrared transmissive, anti-reflective layer being substantially non-reflective to visible light frequencies.Type: ApplicationFiled: May 18, 2017Publication date: October 8, 2020Applicant: Strata Designs LimitedInventor: David BEER
-
Publication number: 20140057794Abstract: The present disclosure relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present disclosure relates to cancer markers as diagnostic markers and clinical targets for lung cancer.Type: ApplicationFiled: August 21, 2013Publication date: February 27, 2014Applicant: The Regents of the University of MichiganInventors: David Beer, Jeremy Taylor, Guoan Chen, Sinae Kim
-
Patent number: 8617547Abstract: The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ubiquilin 1 markers for cancer.Type: GrantFiled: September 10, 2009Date of Patent: December 31, 2013Assignee: The Regents of The University of MichiganInventors: Arul Chinnaiyan, David Beer, Guoan Chen, Xiaoju Wang
-
Publication number: 20120295803Abstract: The present disclosure relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present disclosure relates to cancer markers as diagnostic markers and clinical targets for lung cancer.Type: ApplicationFiled: May 16, 2012Publication date: November 22, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: David Beer, Jeremy Taylor, Guoan Chen, Sinae Kim
-
Patent number: 7955602Abstract: The present invention relates to screening methods for diagnosis, prognosis, or susceptibility to cancer in a subject by means of detecting the presence of serum autoantibodies to specific annexin protein antigens in sera from subjects. The present invention also provides screening methods for diagnosis and prognosis of cancer in a subject by means of detecting increased expression levels of annexin proteins in biological samples of the subject. The method of the invention can also be used to identify subjects at risk for developing cancer. The method of the invention involves the use of subject derived biological samples to determine the occurrence and level of expression of annexin proteins or expression of annexin derived peptides or antigens, and/or the occurrence and level of circulating autoantibodies to specific annexin protein antigens. The present invention further provides for kits for carrying out the above described screening methods.Type: GrantFiled: June 10, 2010Date of Patent: June 7, 2011Assignee: Regents of the University of MichiganInventors: Samir M. Hanash, David Misek, Robert Hinderer, David Beer, Frank Brichory
-
Publication number: 20100330587Abstract: The present invention relates to screening methods for diagnosis, prognosis, or susceptibility to cancer in a subject by means of detecting the presence of serum autoantibodies to specific annexin protein antigens in sera from subjects. The present invention also provides screening methods for diagnosis and prognosis of cancer in a subject by means of detecting increased expression levels of annexin proteins in biological samples of the subject. The method of the invention can also be used to identify subjects at risk for developing cancer. The method of the invention involves the use of subject derived biological samples to determine the occurrence and level of expression of annexin proteins or expression of annexin derived peptides or antigens, and/or the occurrence and level of circulating autoantibodies to specific annexin protein antigens. The present invention further provides for kits for carrying out the above described screening methods.Type: ApplicationFiled: June 10, 2010Publication date: December 30, 2010Applicant: Regents of the University of MichiganInventors: Samir M. Hanash, David Misek, Robert Hinderer, David Beer, Franck Brichory
-
Patent number: 7759081Abstract: The present invention relates to screening methods for diagnosis, prognosis, or susceptibility to cancer in a subject by means of detecting the presence of serum autoantibodies to specific annexin protein antigens in sera from subjects. The present invention also provides screening methods for diagnosis and prognosis of cancer in a subject by means of detecting increased expression levels of annexin proteins in biological samples of the subject. The method of the invention can also be used to identify subjects at risk for developing cancer. The method of the invention involves the use of subject derived biological samples to determine the occurrence and level of expression of annexin proteins or expression of annexin derived peptides or antigens, and/or the occurrence and level of circulating autoantibodies to specific annexin protein antigens. The present invention further provides for kits for carrying out the above described screening methods.Type: GrantFiled: June 21, 2006Date of Patent: July 20, 2010Assignee: Regents of the University of MichiganInventors: Samir M. Hanash, David Misek, Robert Hinderer, David Beer, Franck Brichory
-
Publication number: 20100009382Abstract: The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ubiquilin 1 markers for cancer.Type: ApplicationFiled: September 10, 2009Publication date: January 14, 2010Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Arul Chinnaiyan, David Beer, Guoan Chen, Xiaoju Wang
-
Patent number: 7597890Abstract: The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ubiquilin 1 markers for cancer.Type: GrantFiled: March 8, 2007Date of Patent: October 6, 2009Assignee: The Regents of the University of MichiganInventors: Arul Chinnaiyan, David Beer, Guoan Chen, Xiaoju Wang
-
Publication number: 20080044839Abstract: The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ubiquilin 1 markers for cancer.Type: ApplicationFiled: March 8, 2007Publication date: February 21, 2008Applicant: Regents of the University of MichiganInventors: Arul Chinnaiyan, David Beer, Guoan Chen, Xiaoju Wang
-
Publication number: 20070148713Abstract: Computerized analysis of 2-D gels, both carrier ampholyte (CA) and immobilized pH gradient (IPG) based, of the proteins in tissue from esophageal tumors, reveals proteins which are different in tumor and control tissue.Type: ApplicationFiled: October 12, 2006Publication date: June 28, 2007Inventors: Samir Hanash, David Beer, Rork Kuick, Robert Hinderer
-
Publication number: 20070037227Abstract: The present invention relates to screening methods for diagnosis, prognosis, or susceptibility to cancer in a subject by means of detecting the presence of serum autoantibodies to specific annexin protein antigens in sera from subjects. The present invention also provides screening methods for diagnosis and prognosis of cancer in a subject by means of detecting increased expression levels of annexin proteins in biological samples of the subject. The method of the invention can also be used to identify subjects at risk for developing cancer. The method of the invention involves the use of subject derived biological samples to determine the occurrence and level of expression of annexin proteins or expression of annexin derived peptides or antigens, and/or the occurrence and level of circulating autoantibodies to specific annexin protein antigens. The present invention further provides for kits for carrying out the above described screening methods.Type: ApplicationFiled: June 21, 2006Publication date: February 15, 2007Inventors: Samir Hanash, David Misek, Robert Hinderer, David Beer, Franck Brichory
-
Publication number: 20060275845Abstract: The present invention relates to screening methods for diagnosis, prognosis, or susceptibility to cancer in a subject by means of detecting the presence of serum autoantibodies to specific annexin protein antigens in sera from subjects. The present invention also provides screening methods for diagnosis and prognosis of cancer in a subject by means of detecting increased expression levels of annexin proteins in biological samples of the subject. The method of the invention can also be used to identify subjects at risk for developing cancer. The method of the invention involves the use of subject derived biological samples to determine the occurrence and level of express on of annexin proteins or expression of annexin derived peptides or antigens, and/or the occurrence and level of circulating autoantibodies to specific annexin protein antigens. The present invention further provides for kits for carrying out the above described screening methods.Type: ApplicationFiled: June 21, 2006Publication date: December 7, 2006Inventors: Samir HANASH, David Misek, Robert Hinderer, David Beer, Franck Brichory
-
Publication number: 20040048320Abstract: The present invention relates to screening methods for diagnosis, prognosis, or susceptibility to cancer in a subject by means of detecting the presence of serum autoantibodies to specific annexin protein antigens in sera from subjects. The present invention also provides screening methods for diagnosis and prognosis of cancer in a subject by means of detecting increased expression levels of annexin proteins in biological samples of the subject. The method of the invention can also be used to identify subjects at risk for developing cancer. The method of the invention involves the use of subject derived biological samples to determine the occurrence and level of expression of annexin proteins or expression of annexin derived peptides or antigens, and/or the occurrence and level of circulating autoantibodies to specific annexin protein antigens. The present invention further provides for kits for carrying out the above described screening methods.Type: ApplicationFiled: September 5, 2003Publication date: March 11, 2004Inventors: Samir M. Hanash, David Misek, Robert Hinderer, David Beer, Frank Brichory
-
Patent number: 6645465Abstract: The present invention relates to screening methods for diagnosis, prognosis, or susceptibility to cancer in a subject by means of detecting the presence of serum autoantibodies to specific annexin protein antigens in sera from subjects. The present invention also provides screening methods for diagnosis and prognosis of cancer in a subject by means of detecting increased expression levels of annexin proteins in biological samples of the subject. The method of the invention can also be used to identify subjects at risk for developing cancer. The method of the invention involves the use of subject derived biological samples to determine the occurrence and level of expression of annexin proteins or expression of annexin derived peptides or antigens, and/or the occurrence and level of circulating autoantibodies to specific annexin protein antigens. The present invention further provides for kits for carrying out the above described screening methods.Type: GrantFiled: August 6, 1999Date of Patent: November 11, 2003Assignee: Michigan, University of the RegentsInventors: Samir M. Hanash, David Misek, Robert Hinderer, David Beer, Franck Brichory
-
Publication number: 20020168696Abstract: The present invention relates to screening methods for diagnosis, prognosis, or susceptibility to cancer in a subject by means of detecting the presence of serum autoantibodies to specific annexin protein antigens in sera from subjects. The present invention also provides screening methods for diagnosis and prognosis of cancer in a subject by means of detecting increased expression levels of annexin proteins in biological samples of the subject. The method of the invention can also be used to identify subjects at risk for developing cancer. The method of the invention involves the use of subject derived biological samples to determine the occurrence and level of expression of annexin proteins or expression of annexin derived peptides or antigens, and/or the occurrence and level of circulating autoantibodies to specific annexin protein antigens. The present invention further provides for kits for carrying out the above described screening methods.Type: ApplicationFiled: August 6, 1999Publication date: November 14, 2002Inventors: SAMIR M. HANASH, DAVID MISEK, ROBERT HINDERER, DAVID BEER, FRANCK BRICHORY